Dihydroergotamine - Impel NeuroPharma

Drug Profile

Dihydroergotamine - Impel NeuroPharma

Alternative Names: INP-104; POD-DHE

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Impel NeuroPharma
  • Class Antimigraines; Ergotamines; Mesylates; Small molecules
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Migraine

Most Recent Events

  • 03 Nov 2017 Phase-I clinical trials in Migraine (In volunteers) in Australia (Intranasal) (ACTRN12617001381370p)
  • 31 Oct 2017 Impel NeuroPharma announces intention to submit NDA to the US FDA for Migraine in 2019
  • 31 Oct 2017 Impel NeuroPharma plans a pivotal safety trial for Migraine in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top